Alpha-Lapachone

Alpha-Lapachone

SCHEMBL102553

CC1(C)CCC2=C(O1)C(=O)c1ccccc1C2=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 9/20 1.00
MALT1 Q9UDY8 9/20 0.79
LMNA P02545 2/20 0.79
KDM4E B2RXH2 1/20 0.79
MEN1 O00255 1/20 0.79
CES2 O00748 1/20 0.79
GMNN O75496 1/20 0.79
TDP2 O95551 1/20 0.79
ALDH1A1 P00352 1/20 0.79
TP53 P04637 1/20 0.79
CYP1A2 P05177 1/20 0.79
GLA P06280 1/20 0.79
CYP3A4 P08684 1/20 0.79
CYP2D6 P10635 1/20 0.79
MAPT P10636 1/20 0.79
HSPD1 P10809 1/20 0.79
THRB P10828 1/20 0.79
CYP2C9 P11712 1/20 0.79
NQO1 P15559 1/20 0.79
ALOX15 P16050 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alpha-Lapachone SCHEMBL29355317 1.00 IDO1 (1.00) IDO1MALT1LMNAKDM4EMEN1
Lapachone SCHEMBL29351050 0.89 MALT1 (1.00) IDO1MALT1LMNAKDM4EMEN1
Lapachone SCHEMBL107042 0.89 MALT1 (1.00) IDO1MALT1LMNAKDM4EMEN1
SCHEMBL18790870 0.83 IDO1 (0.71) IDO1MALT1LMNAKDM4EMEN1
SCHEMBL15034364 0.81 MALT1 (0.76) IDO1MALT1LMNAKDM4EMEN1
SCHEMBL8186444 0.81 MALT1 (0.76) IDO1MALT1LMNAKDM4EMEN1
SCHEMBL10916020 0.79 MALT1 (0.72) IDO1MALT1LMNAKDM4EMEN1
SCHEMBL10916022 0.79 MALT1 (0.72) IDO1MALT1LMNAKDM4EMEN1
SCHEMBL28836927 0.79 IDO1 (0.64) IDO1MALT1LMNAKDM4EMEN1
SCHEMBL104546 0.78 IDO1 (0.63) IDO1MALT1LMNAKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114209676-B Nanometer diagnosis and treatment material and application thereof 浙江大学杭州国际科创中心 2023-06-13 CN disclosed
CN-114209676-A Nano diagnosis and treatment material and application thereof 浙江大学杭州国际科创中心 2022-03-22 CN disclosed
WO-2017070012-A1 LAPACHONE DERIVATIVES CONTAINING TWO REDOX CENTERS AND METHODS OF USE THEREOF THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-04-27 WO disclosed
EP-2301520-B1 Oxidative dye HENKEL AG & CO KGAA (DE) 2017-03-08 EP disclosed
EP-2137168-B1 NOVEL IDO INHIBITORS AND METHODS OF USE THEREOF LANKENAU INST MEDICAL RES (US) 2016-09-14 EP disclosed
US-20130183388-A1 Novel IDO Inhibitors and Methods of Use Thereof LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) 2013-07-18 US disclosed
US-20130183388-A1 Novel IDO Inhibitors and Methods of Use Thereof LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) 2013-07-18 US disclosed
US-8389568-B2 IDO inhibitors and methods of use thereof LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) 2013-03-05 US disclosed
US-8389568-B2 IDO inhibitors and methods of use thereof LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) 2013-03-05 US disclosed
EP-2426212-A1 Method for controlling NAD(P)/NAD(P)H ratio by oxidoreductase Md Bioalpha Co., Ltd. (KR) 2012-03-07 EP disclosed
US-20090215145-A1 METHOD FOR CONTROLLING NAD(P)/NAD(P)H RATIO BY OXIDOREDUCTASE MD BIOALPHA CO., LTD. (KR) 2009-08-27 US disclosed
US-20090215145-A1 METHOD FOR CONTROLLING NAD(P)/NAD(P)H RATIO BY OXIDOREDUCTASE MD BIOALPHA CO., LTD. (KR) 2009-08-27 US disclosed
WO-2009060017-A1 HAIR TREATMENT AGENT COMPRISING TILIROSIDE AND VITAMIN B HENKEL AG & CO. KGAA (DE) 2009-05-14 WO disclosed
WO-2009033833-A2 COLORING AGENT HAVING NATURAL DYES AND 1,3-DIHYDROXYACETONE HENKEL AG & CO. KGAA (DE) 2009-03-19 WO disclosed
WO-2008115804-A1 NOVEL IDO INHIBITORS AND METHODS OF USE THEREOF LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) 2008-09-25 WO disclosed
EP-1567515-A4 NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF ARQULE INC (US) 2008-04-23 EP disclosed
WO-2007094632-A1 METHOD FOR CONTROLLING NAD(P)/NAD(P)H RATIO BY OXIDOREDUCTASE MD BIOALPHA CO., LTD. (KR) 2007-08-23 WO disclosed
EP-1567515-A2 NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF ARQULE, INC. (US) 2005-08-31 EP disclosed
US-20040266857-A1 Novel lapachone compounds and methods of use thereof HINES GLOBAL EDUCATION 2004-12-30 US disclosed
WO-2004045557-A2 NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF ARQULE, INC. (US) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266857-A1 Novel lapachone compounds and methods of use thereof XIAP, MKI67, PIN1 IDO1 1021/4885MALT1 598/4885LMNA 67/4885
US-20130183388-A1 Novel IDO Inhibitors and Methods of Use Thereof IDO1, IDO2, INMT IDO1 1/4885MALT1 1031/4885LMNA 4874/4885
US-20090215145-A1 METHOD FOR CONTROLLING NAD(P)/NAD(P)H RATIO BY OXIDOREDUCTASE NQO1, NADK, ME2 IDO1 1756/4885MALT1 4170/4885LMNA 1441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.